The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Abstract
The RET gene encodes a receptor tyrosine kinase that is expressed in neural crest-derived cell lineages. The RET receptor plays a crucial role in regulating cell proliferation, migration, differentiation, and survival through embryogenesis. Activating mutations in RET lead to the development of several inherited and noninherited diseases. Germline point mutations are found in the cancer syndromes multiple endocrine neoplasia (MEN) type 2, including MEN 2A and 2B, and familial medullary thyroid carcinoma. These syndromes are autosomal dominantly inherited. The identification of mutations associated with these syndromes has led to genetic testing to identify patients at risk for MEN 2 and familial medullary thyroid carcinoma and subsequent implementation of prophylactic thyroidectomy in mutation carriers. In addition, more than 10 somatic rearrangements of RET have been identified from papillary thyroid carcinomas. These mutations, as those found in MEN 2, induce oncogenic activation of the RET tyrosine kinase domain via different mechanisms, making RET an excellent candidate for the design of molecular targeted therapy. Recently, various kinds of therapeutic approaches, such as tyrosine kinase inhibition, gene therapy with dominant negative RET mutants, monoclonal antibodies against oncogene products, and nuclease-resistant aptamers that recognize and inhibit RET have been developed. The use of these strategies in preclinical models has provided evidence that RET is indeed a potential target for selective cancer therapy. However, a clinically useful therapeutic option for treating patients with RET-associated cancer is still not available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedNeutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
Cerchia, L., Ducongé, F., Pestourie, C., Boulay, J., Aissouni, Y., Gombert, K., Tavitian, B., de Franciscis, V., & Libri, D. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030123 · Cited by 246
RetractedSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Cited by
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
Nikiforova, M. N., Wald, A. I., Roy, S., Durso, M. B., & Nikiforov, Y. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2292 · Cited by 485
A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo
Samadi, A. K., Mukerji, R., Shah, A., Timmermann, B. N., & Cohen, M. S. (2010) · Surgery · doi:10.1016/j.surg.2010.09.026 · Cited by 60
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58
Metadata
- Authors
- de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., & Hofstra, R. M. W.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2006-07-18
- Volume
- 27
- Issue
- 5
- Pages
- 535-560
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2092228137
- Cited by
- 356
- References
- 194
- FWCI
- 14.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors. https://app.cochat.ai/papers/10.1210/er.2006-0017
- The paper
- de Groot, J. W. B., Links, T. P., Plukker, J. T. M., Lips, C. J. M., & Hofstra, R. M. W. (2006). RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors. Endocrine Reviews. https://doi.org/10.1210/er.2006-0017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
